Nektar falls on TNBC data for doublet, but considering moving ahead with a triple combo

Despite shedding over $200 million from its market cap Thursday after reporting response data from the triple-negative breast cancer cohort of its bempegaldesleukin/Opdivo nivolumab combination trial, Nektar is looking ahead to the next set of trials for the combo.

In the Phase I/II PIVOT-02 trial, Nektar Therapeutics (NASDAQ:NKTR) said bempegaldesleukin plus the PD-1 inhibitor led to a confirmed overall response rate of 13% in 38 TNBC patients, regardless of PD-L1 expression. All five responders had received at least one prior line of chemotherapy. In a subgroup of 24 patients who had received at least two prior lines of the therapy, the ORR was 21% (5/24). There was little difference in response rates among PD-L1 negative patients at 14% ( 3/22) and PD-L1-positive patients at 17% (2/12). ...